ALK and non-small cell lung carcinoma: For RP2D determination in ALK TKI-naïve, advanced ALK-positive NSCLC patients, an 800-mg QD dose of conteltinib was excluded owing to its saturated drug absorption and a high potential of high-grade toxicities.